GlassScriptPhysician profile
David Paul Bernstein
NPI 1700863727
$4,268.85
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $312 · 2021: $1,196 · 2022: $1,007 · 2023: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,065.71 | 2019-2023 | Xtandi, Myrbetriq |
| Coloplast Corp | $837.61 | 2019-2023 | Speedicath, Titan |
| Pfizer INC. | $401.85 | 2019-2023 | |
| Abbvie INC. | $291.39 | 2019-2023 | Botox |
| Janssen Biotech, INC. | $202.23 | 2019-2023 | Erleada |
| Allergan, INC. | $174.35 | 2019-2021 | |
| Myovant Sciences INC. | $140.25 | 2021-2022 | |
| Boston Scientific Corporation | $136.29 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $118.73 | 2023 | Orgovyx, Gemtesa |
| Janssen Scientific Affairs, LLC | $118.37 | 2019 | |
| Medtronic, INC. | $96.18 | 2022 | |
| Teleflex LLC | $86.21 | 2021 | |
| Urovant Sciences INC | $72.09 | 2021-2022 | |
| Procept Biorobotics Corporation | $67.25 | 2022 | |
| Blue Earth Diagnostics | $62.25 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $61.99 | 2022-2023 | Jelmyto |
| Endo Pharmaceuticals INC. | $58.81 | 2023 | Aveed, Xiaflex, Edex |
| Tolmar, INC. | $45.26 | 2023 | |
| 180 Medical, INC. | $31.69 | 2019 | |
| Clarus Therapeutics INC. | $25.26 | 2021 | |
| Rochester Medical Corporation | $23.45 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $19.55 | 2022 | |
| Progenics Pharmaceuticals, INC. | $19.19 | 2022 | |
| Verity Pharmaceuticals INC. | $17.89 | 2022 | |
| Merck Sharp & Dohme LLC | $16.19 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.10 | 2023 | Oxlumo |
| Amgen INC. | $14.96 | 2020 | |
| Mission Pharmacal Company | $13.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.78 | 2022 | |
| Antares Pharma, INC. | $11.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.